Complementary therapy to target LDL cholesterol: The role of the ezetimibe/simvastatin combination

Ryan C. Neal; Peter H. Jones

doi:10.2147/vhrm.2006.2.1.31

Complementary therapy to target LDL cholesterol: The role of the ezetimibe/simvastatin combination

Ryan C. Neal, Peter H. Jones

Research output: Contribution to journal › Review article › peer-review

17 Scopus citations

Abstract

Cardiovascular (CV) disease remains the number 1 cause of death in the USA. Nonetheless, there has been a decline in the age-adjusted death rate for coronary heart disease (CHD) which may be due to more aggressive treatment guidelines for treating CV risk factors, such as hypertension, diabetes, and dyslipidemia. The recent update to the National Cholesterol Education Program (NCEP) guidelines have recommended lower low-density lipoprotein cholesterol (LDL-C) goals in high-risk patients. Based on the new targets for LDL-C, clinicians will need more efficacious lipid-lowering therapies. One of these newer therapies is the combination of ezetimibe and simvastatin. This article reviews the implications of the updated guidelines and discusses the efficacy and safety of ezetimibe/simvastatin for lowering LDL-C.

Original language	English (US)
Pages (from-to)	31-38
Number of pages	8
Journal	Vascular Health and Risk Management
Volume	2
Issue number	1
DOIs	https://doi.org/10.2147/vhrm.2006.2.1.31
State	Published - 2006

Keywords

Combination lipid treatment
Ezetimibe
Statin

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Hematology
Public Health, Environmental and Occupational Health
Cardiology and Cardiovascular Medicine
Pharmacology (medical)

Access to Document

10.2147/vhrm.2006.2.1.31

Cite this

@article{0adcb93f4d3f46858081eb7a724a52a5,

title = "Complementary therapy to target LDL cholesterol: The role of the ezetimibe/simvastatin combination",

abstract = "Cardiovascular (CV) disease remains the number 1 cause of death in the USA. Nonetheless, there has been a decline in the age-adjusted death rate for coronary heart disease (CHD) which may be due to more aggressive treatment guidelines for treating CV risk factors, such as hypertension, diabetes, and dyslipidemia. The recent update to the National Cholesterol Education Program (NCEP) guidelines have recommended lower low-density lipoprotein cholesterol (LDL-C) goals in high-risk patients. Based on the new targets for LDL-C, clinicians will need more efficacious lipid-lowering therapies. One of these newer therapies is the combination of ezetimibe and simvastatin. This article reviews the implications of the updated guidelines and discusses the efficacy and safety of ezetimibe/simvastatin for lowering LDL-C.",

keywords = "Combination lipid treatment, Ezetimibe, Statin",

author = "Neal, {Ryan C.} and Jones, {Peter H.}",

year = "2006",

doi = "10.2147/vhrm.2006.2.1.31",

language = "English (US)",

volume = "2",

pages = "31--38",

journal = "Vascular Health and Risk Management",

issn = "1176-6344",

publisher = "Dove Medical Press Ltd.",

number = "1",

}

TY - JOUR

T1 - Complementary therapy to target LDL cholesterol

T2 - The role of the ezetimibe/simvastatin combination

AU - Neal, Ryan C.

AU - Jones, Peter H.

PY - 2006

Y1 - 2006

N2 - Cardiovascular (CV) disease remains the number 1 cause of death in the USA. Nonetheless, there has been a decline in the age-adjusted death rate for coronary heart disease (CHD) which may be due to more aggressive treatment guidelines for treating CV risk factors, such as hypertension, diabetes, and dyslipidemia. The recent update to the National Cholesterol Education Program (NCEP) guidelines have recommended lower low-density lipoprotein cholesterol (LDL-C) goals in high-risk patients. Based on the new targets for LDL-C, clinicians will need more efficacious lipid-lowering therapies. One of these newer therapies is the combination of ezetimibe and simvastatin. This article reviews the implications of the updated guidelines and discusses the efficacy and safety of ezetimibe/simvastatin for lowering LDL-C.

AB - Cardiovascular (CV) disease remains the number 1 cause of death in the USA. Nonetheless, there has been a decline in the age-adjusted death rate for coronary heart disease (CHD) which may be due to more aggressive treatment guidelines for treating CV risk factors, such as hypertension, diabetes, and dyslipidemia. The recent update to the National Cholesterol Education Program (NCEP) guidelines have recommended lower low-density lipoprotein cholesterol (LDL-C) goals in high-risk patients. Based on the new targets for LDL-C, clinicians will need more efficacious lipid-lowering therapies. One of these newer therapies is the combination of ezetimibe and simvastatin. This article reviews the implications of the updated guidelines and discusses the efficacy and safety of ezetimibe/simvastatin for lowering LDL-C.

KW - Combination lipid treatment

KW - Ezetimibe

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=33646029692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646029692&partnerID=8YFLogxK

U2 - 10.2147/vhrm.2006.2.1.31

DO - 10.2147/vhrm.2006.2.1.31

M3 - Review article

C2 - 17319467

AN - SCOPUS:33646029692

SN - 1176-6344

VL - 2

SP - 31

EP - 38

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

IS - 1

ER -

Complementary therapy to target LDL cholesterol: The role of the ezetimibe/simvastatin combination

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this